Moderna shares climbed 2.52% in the most recent session, outperforming the Nasdaq Biotech index which dipped 1.3% over the same period. Average daily trading volume rose by 18% to 7.4 million shares, suggesting renewed investor interest in the company’s late-stage pipeline. This uptick comes despite weakness in large-cap tech and healthcare peers, underscoring confidence in Moderna’s strategic repositioning.

Management reiterated its goal of reaching cash break-even by 2028 through a disciplined reallocation of resources toward infectious disease, oncology and rare diseases. Vaccine revenues, which peaked at $18 billion in 2021, have since moderated; Moderna projects $3.2 billion of product sales this year. The company expects key data readouts in 2026 for its Intismeran/Keytruda combination, with Phase II results due in mid-year and a pivotal Phase III trial scheduled to report by year-end.

At the 44th Annual J.P. Morgan Healthcare Conference, CEO Stéphane Bancel highlighted three FDA-approved respiratory vaccines and two additional filings under regulatory review for influenza and combination flu/COVID candidates. A norovirus vaccine is in Phase III, while the oncology portfolio features over a dozen mRNA-based programs. Management emphasized that respiratory franchise revenues will fund accelerated development across oncology and rare disease assets, aiming to launch the first oncology indication by 2027.